{"title":"修正“阿西卡他格西鲁塞对既往治疗2线或以上后复发或难治性大b细胞淋巴瘤的老年患者和/或ECOG表现较差的患者的获益”","authors":"","doi":"10.1002/ajh.27551","DOIUrl":null,"url":null,"abstract":"<p>Lunning MA, Wang HL, Hu ZH, et al., “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy,” <i>American Journal of Hematology</i> 99, no. 5 (2024): 880–889.</p>\n<p>In Figure 1C, a typographical error was made reporting incorrect median overall survival (OS) values for the axi-cel and chemoimmunotherapy (CIT) arms by Eastern Cooperative Oncology Group performance status (ECOG PS). The correct values are reported in Table S2 and are reproduced here:</p>\n<p>Median OS (95% CI).</p>\n<p>Axi-cel, ECOG PS < 2 (<i>n</i> = 526): 28.0 months (20.8-NE).</p>\n<p>CIT, ECOG PS < 2 (<i>n</i> = 296): 6.4 months (5.7–7.6).</p>\n<p>Axi-cel, ECOG PS = 2 (<i>n</i> = 33): 3.6 months (2.3–8.1).</p>\n<p>CIT, ECOG PS = 2 (<i>n</i> = 27): 2.7 months (1.4–5.1).</p>\n<p>We apologize for this error.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"88 1","pages":""},"PeriodicalIF":10.1000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy”\",\"authors\":\"\",\"doi\":\"10.1002/ajh.27551\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Lunning MA, Wang HL, Hu ZH, et al., “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy,” <i>American Journal of Hematology</i> 99, no. 5 (2024): 880–889.</p>\\n<p>In Figure 1C, a typographical error was made reporting incorrect median overall survival (OS) values for the axi-cel and chemoimmunotherapy (CIT) arms by Eastern Cooperative Oncology Group performance status (ECOG PS). The correct values are reported in Table S2 and are reproduced here:</p>\\n<p>Median OS (95% CI).</p>\\n<p>Axi-cel, ECOG PS < 2 (<i>n</i> = 526): 28.0 months (20.8-NE).</p>\\n<p>CIT, ECOG PS < 2 (<i>n</i> = 296): 6.4 months (5.7–7.6).</p>\\n<p>Axi-cel, ECOG PS = 2 (<i>n</i> = 33): 3.6 months (2.3–8.1).</p>\\n<p>CIT, ECOG PS = 2 (<i>n</i> = 27): 2.7 months (1.4–5.1).</p>\\n<p>We apologize for this error.</p>\",\"PeriodicalId\":7724,\"journal\":{\"name\":\"American Journal of Hematology\",\"volume\":\"88 1\",\"pages\":\"\"},\"PeriodicalIF\":10.1000,\"publicationDate\":\"2024-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ajh.27551\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ajh.27551","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy”
Lunning MA, Wang HL, Hu ZH, et al., “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy,” American Journal of Hematology 99, no. 5 (2024): 880–889.
In Figure 1C, a typographical error was made reporting incorrect median overall survival (OS) values for the axi-cel and chemoimmunotherapy (CIT) arms by Eastern Cooperative Oncology Group performance status (ECOG PS). The correct values are reported in Table S2 and are reproduced here:
期刊介绍：
The American Journal of Hematology offers extensive coverage of experimental and clinical aspects of blood diseases in humans and animal models. The journal publishes original contributions in both non-malignant and malignant hematological diseases, encompassing clinical and basic studies in areas such as hemostasis, thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports highlighting innovative therapeutic approaches for the diagnosis and treatment of hematological diseases are actively encouraged.The American Journal of Hematology features regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, as well as letters and correspondence.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
